Deutsche Bank
http://www.db.com/
Deutsche Bank is a leading global investment bank with a strong and profitable private clients franchise.
The company operates through three divisions: Corporate and Investment Bank (CIB), Private Clients and Asset Management (PCAM) and Corporate Investments (CI) . The CIB division engages in the origination, sale, financing, structuring, and trading of fixed income, equity, equity-linked, convertible bond, foreign exchange, and commodities products. The PCAM segment provides portfolio/fund management products, including active fund management, passive/quantitative fund management, alternative investments, and discretionary portfolio management solutions in Germany and other continental European countries.-
Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference
-
Scripts Data Indicates Biogen's (BIIB) Tecfidera Could Beat 2013 Estimates by $400M
-
Deutsche Bank Sees Upside for Biogen's (BIIB) Tecfidera
-
Deutsche Bank Maintains Buy on Biogen (BIIB)
-
Deutsche Bank Raises Biogen (BIIB) Price Target to $240
-
Notable 52-Week Highs and Lows of the Day 04/22: (HAS) (CELG) (RAD) High; (MHR) (BTU) Low
-
Deutsche Bank Boosts PT on Biogen (BIIB) to $170 on Tysabri Deal
-
Baxter (BAX) Smacked on Solid Results from Biogen's (BIIB) Hemophilia Drug
-
Q2 Kickoff: Alcoa (AA) Investors to Focus on LME Prices, Downstream Ops, and China
-
Deutsche Bank maintains a 'Buy' on Biogen Idec (BIIB); Hemophilia Survey Suggests Market Share Gains
-
Biogen Idec (BIIB) volatility flat shares near record high
-
Notable Analyst Rating Changes 09/09: (DB) (SUN) (TWX) Upgraded; (RIMM) (REGN) (SNY) Downgraded
-
Notable Analyst Rating Changes 06/21: (BIIB) (DFS) (SNCR) Upgraded; (PNC) (RIMM) (MMI) Downgraded
-
Deutsche Bank Upgrades Biogen (BIIB) to Buy
-
Notable Analyst Rating Changes 06/18: (MCP) (PCX) (MRVL) Upgraded; (SWKS) (CDXS) (RIMM) Downgraded
-
Biogen Idec (BIIB) volatility low; shares up 6% on positive top-line results
-
Notable Analyst Rating Changes 1/19: EVVV, CIEN, JDSU, X Upgraded; IMAX, PAET, JASO, AKS Downgraded
-
Notable Analyst Rating Changes 1/5: RSH, QCOM, BIIB, AXL, More Upgraded; CBY, V, BEXP, COG, CXO, More Downgraded
-
Goldman Sachs Tells Clients To Buy Biogen Idec (BIIB) on Today's Weakness
-
Notable Analyst Rating Changes 6/29: DFS, LYG, TRW, BCS, JCP Upgraded; AA, SNY, BIIB, WW Downgraded
-
Biogen Idec (BIIB) volatility low into 10th PML case
-
Deutsche Bank Downgrades Biogen-IDEC (BIIB) to Hold; Valuation Call
-
David Moenning's Daily State of the Markets: 4/17
-
Notable Analyst Rating Changes 1/27: CAT, TXN, BIIB Upgraded; VMW, GNK, DRIV, ADP Downgraded
-
Notable Analyst Rating Changes 11/03: WMT, BIIB, NVDA, SLB Upgraded; SSCC, DO, HAL, PHM Downgraded
-
Morning Movers 11/03: VeraSun (VSE) Sinks On Bankrupcty; Goodyear (GT) and Oshkosh (OSK) Up On Results
-
Deutsche Bank Upgrades Biogen Idec (BIIB) to Buy
-
David Moenning's Daily State of the Markets: 10/29
-
Morning Movers 10/10: Morgan Stanley (MS) Slammed Again on Liquidity Fears, Moody's Downgrade; Wachovia (WB) Up
-
Deutsche Bank Notes Tysabri PML Patients are Recovering (BIIB, ELN)
-
Biogen Idec (BIIB) Sinks on TYSABRI PML Fears, Wall Street Comments...
-
David Moenning's Daily State of the Markets: 7/21
-
Notable Analyst Rating Changes 7/21: BIIB, AMR, AIG, BCSI Upgraded; SWK, TWC, DEO, SHW Downgraded
-
Pre-Open Movers 7/21: Genentech (DNA) Higher on Bid for Roche; BofA (BAC) Up on Results
-
Deutsche Bank Starts Biogen-IDEC (BIIB) at Hold
-
Deutsche Bank Starts Coverage on Large Biotechs; DNA, GILD & AMGN Rated Buys, BIIB & GENZ Rated Holds
-
Notable Analyst Rating Changes 1/15: STO, NOC, BIIB Upgraded; BP, SLB, GRMN, HAR Downgraded
